An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers.
Ontology highlight
ABSTRACT: Multigene signatures generate crucial prognostic information particularly useful for cancer patients where clinical parameters and traditional immunohistochemical markers alone lead to equivocal prognosis. Clinicians are now provided with molecular tools that assist in the outline of adjuvant therapies, namely helping decide on the extension of adjuvant endocrine therapy or on suppressing adjuvant chemotherapy in patients were toxic effects are particularly deleterious or when this treatment is fundamentally not needed. The importance of cancer multigene prognostic signatures is well elucidated in the guidelines for adjuvant systemic therapy in early-stage breast cancer and the guidelines on disease staging that are progressively integrating gene expression assays as classification biomark
SUBMITTER: Vieira AF
PROVIDER: S-EPMC6131478 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA